EBRO 2017

First page Table of contents Previous page 34 Next page Last page

Personalised medicine

• PFS2/PFS1 >1.3 in 33% (63/193) • 7% of the successfully screened patients benefited from this approach

Massard Cancer Discov; 2017

ESTRO: Evidence-based Radiation Oncology

Made with FlippingBook Learn more on our blog